Annual Drug Patent Expirations for QTERN
Qtern is a drug marketed by Astrazeneca Ab and is included in two NDAs. It is available from one supplier. There are nine patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for QTERN.
This drug has three hundred and thirty-nine patent family members in forty-eight countries.
The generic ingredient in QTERN is dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride. One supplier is listed for this compound. Additional details are available on the dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
